Target Audience: Practicing ophthalmologists who care for patients with glaucoma and related disorders.
- Effectively evaluate current and new diagnostic testing modalities to assist in the early diagnosis of the glaucoma patient and glaucoma suspect as well as disease progression.
- Make treatment decisions using evidence-based recommendations regarding the use of medical and laser therapies for the treatment of glaucoma.
- Evaluate best phacoemulsification treatment options and considerations for patients with complex, pre-existing and advance glaucoma
- Compare recent and emerging microinvasive glaucoma surgical (MIGS) options.
- Integrate pearls to improve glaucoma surgical outcomes.
- Implement strategies to manage glaucoma surgical challenges.
The American Society of Cataract and Refractive Surgery is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. ASCRS takes responsibility for the content, quality and scientific integrity of the CME activity.
The American Society of Cataract and Refractive Surgery designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
All CME activities approved for AMA PRA Category 1 Credits™ are valid for recognition by the European Accreditation Council for Continuing Medical Education (EACCME). Physicians not licensed in the U.S. who participate in this CME activity are eligible for AMA PRA Category 1 Credits™.
Claim CME/CE Credits
Attendees will be able to evaluate Glaucoma Day 2020 through the Claim CME/CE Credit Stations. When the evaluation is complete, attendees can print or email a copy of the certificate for continuing education credits for that day. If attendees do not complete the evaluations during the meeting, they will have the opportunity to complete them at home. Deadline is May 28, 2020. Evaluations for Glaucoma Day 2020 are also available through the meeting app.
Notice About Off-Label Use Presentations
The ASCRS Annual Meeting may include presentations on drugs or devices or uses of drugs or devices that may not have been approved by the Food and Drug Administration (FDA) or have been approved by the FDA for specific uses only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.
ASCRS is committed to the free exchange of medical education. Inclusion of any presentation in this program, including presentations of off-label uses, does not imply an endorsement by ASCRS of the uses, products or techniques presented.